Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Study to Evaluate the Safety and Preliminary Efficacy of Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Next Previous
Trial Profile

Exploratory Study to Evaluate the Safety and Preliminary Efficacy of Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-HER2-CAR-T-cell-therapy-UTC-Therapeutics (Primary) ; Cyclophosphamide; Fludarabine; Paclitaxel
  • Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors UTC Therapeutics

Most Recent Events

  • 19 Mar 2026 Planned End Date changed from 30 Nov 2027 to 30 Apr 2028.
  • 19 Mar 2026 Planned primary completion date changed from 30 Nov 2026 to 30 Apr 2027.
  • 19 Mar 2026 Planned initiation date changed from 30 Nov 2024 to 30 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top